Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729972 · ClinicalTrials.gov registry record · Phase 2
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
A Phase 2 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT04729972 is a Phase 2 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT04729972, a Phase 2 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
Interventions
- COMBINATION_PRODUCT NT-501 CNTF implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04729972
The ClinicalTrials.gov registry entry for NCT04729972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NT-501 CNTF implant is the first listed.
NCT04729972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04729972 about?
NCT04729972 is a clinical study titled "Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2". This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
What is the current status of trial NCT04729972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2021-07-21. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT04729972?
The interventions under investigation include: NT-501 CNTF implant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04729972?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.